Drug details

Kimmtrak (tebentafusp-tebn injection, for intravenous use)

type of Monoclonal Antibodies

Kimmtrak (tebentafusp-tebn) is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

This drug may have the following side effects:

• nausea,
• headache
• vomiting,
• fever,
• chills,
• low blood pressure,
• rash,
• hives, 
• difficulty breathing, 
• swelling of your face, lips, tongue, or throat, 
• fatigue, and
• low oxygen levels in the blood, 
• elevated transaminases, 

The following drugs are related to Kimmtrak, either as a replacement or used together:

• Proleukin (aldesleukin for injection)
• Mektovi (binimetinib tablets)
• Braftovi (encorafenib capsules)
• Tafinlar (dabrafenib capsules)
• Imlygic (talimogene laherparepvec suspension for intralesional injection)
• Intron A (interferon alfa-2b, recombinant for injection)
• Yervoy (ipilimumab injection)
• Keytruda (pembrolizumab for injection)
• Mekinist (trametinib tablets)
• Sylatron (peginterferon alfa-2b)
• Zelboraf (vemurafenib)